A Phase I Study of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors

BACKGROUND: Fenretinide is a synthetic retinoid that can induce cytotoxicity by several mechanisms. Achieving effective systemic exposure with oral formulations has been challenging. An intravenous lipid emulsion fenretinide formulation was developed to overcome this barrier. We conducted a study to...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Chemother Pharmacol
Main Authors: Thomas, Jacob S., El-Khoueiry, Anthony B., Maurer, Barry J., Groshen, Susan, Pinski, Jacek K., Cobos, Everardo, Gandara, David R., Lenz, Heinz J., Kang, Min H, Reynolds, C. Patrick, Newman, Edward M.
Formato: Artigo
Idioma:Inglês
Publicado: 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058950/
https://ncbi.nlm.nih.gov/pubmed/33423090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04224-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares